methane has been researched along with Constipation in 40 studies
Methane: The simplest saturated hydrocarbon. It is a colorless, flammable gas, slightly soluble in water. It is one of the chief constituents of natural gas and is formed in the decomposition of organic matter. (Grant & Hackh's Chemical Dictionary, 5th ed)
methane : A one-carbon compound in which the carbon is attached by single bonds to four hydrogen atoms. It is a colourless, odourless, non-toxic but flammable gas (b.p. -161degreeC).
Constipation: Infrequent or difficult evacuation of FECES. These symptoms are associated with a variety of causes, including low DIETARY FIBER intake, emotional or nervous disturbances, systemic and structural disorders, drug-induced aggravation, and infections.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Bristol stool form, frequency, colon transit time (CTT), and breath methane were evaluated in 23 patients with CC (10 patients with constipation-predominant irritable bowel syndrome [IBS-C], 13 functional constipation, Rome III) and m-ethane production compared with 68 non-constipating IBS." | 9.27 | A randomized double-blind placebo-controlled trial showing rifaximin to improve constipation by reducing methane production and accelerating colon transit: A pilot study. ( Ghoshal, UC; Misra, A; Srivastava, D, 2018) |
| "Adjuvant 5-fluorouracil chemotherapy reduces recurrences in colorectal cancer, but causes severe gastrointestinal toxicity, partly related to disturbed intestinal microbiota." | 9.17 | Colonic methane production modifies gastrointestinal toxicity associated with adjuvant 5-fluorouracil chemotherapy for colorectal cancer. ( Blom, M; Holma, R; Korpela, R; Osterlund, P; Poussa, T; Rautio, M; Sairanen, U; Saxelin, M, 2013) |
| "Recent work has demonstrated that among irritable bowel syndrome (IBS) subjects, methane on lactulose breath test (LBT) is nearly universally associated with constipation predominance." | 9.12 | The degree of breath methane production in IBS correlates with the severity of constipation. ( Chatterjee, S; Kong, Y; Low, K; Park, S; Pimentel, M, 2007) |
| " This subanalysis was done on the constipation-predominant IBS subgroup of patients (C-IBS) to test the ability of neomycin to improve constipation and its correlation with the elimination of methane on breath test." | 9.12 | Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: subanalysis of a double-blind randomized controlled study. ( Chatterjee, S; Chow, EJ; Kong, Y; Park, S; Pimentel, M, 2006) |
| "A growing body of literature suggests an association between methane and constipation." | 8.87 | Methane on breath testing is associated with constipation: a systematic review and meta-analysis. ( Basseri, RJ; Chang, C; Chong, K; Kunkel, D; Makhani, MD; Pimentel, M, 2011) |
| "We found that constipation and bloating severity did not correlate with methane levels on GBT." | 7.96 | Breath Methane Does Not Correlate With Constipation Severity or Bloating in Patients With Constipation. ( Ballou, S; Duehren, S; Iturrino, J; Katon, J; Lembo, A; Nee, J; Patel, R; Rangan, V; Singh, P, 2020) |
| "There is growing evidence that methane production, predominantly by Methanobrevibacter smithii, in the intestines is a cause of constipation, pain, and bloating in irritable bowel syndrome with constipation (IBS-C)." | 7.88 | Development of a Modified-Release Formulation of Lovastatin Targeted to Intestinal Methanogens Implicated in Irritable Bowel Syndrome With Constipation. ( Bristol, A; Chadwick, A; Coughlin, O; Hubert, S; Kokai-Kun, J; Wacher, V, 2018) |
| "Differences in the gut microbiota and breath methane production have been observed in chronic constipation, but the relationship between colonic microbiota, transit, and breath tests remains unclear." | 7.85 | Assessing the colonic microbiome, hydrogenogenic and hydrogenotrophic genes, transit and breath methane in constipation. ( Bharucha, AE; Chen, J; Chia, N; Gaskins, HR; O'Connor, HM; Parthasarathy, G; Wolf, PG, 2017) |
| "Methane (CH4)-producing intestinal bacteria might be related to constipation." | 7.79 | Breath methane positivity is more common and higher in patients with objectively proven delayed transit constipation. ( Choi, MG; Chung, WC; Lee, KM; Paik, CN; Yang, JM, 2013) |
| "Methane excretion is clearly associated with alterations in intestinal motility, particularly favouring those with constipation." | 7.78 | Reassessment of the role of methane production between irritable bowel syndrome and functional constipation. ( Bruzzone, L; Dulbecco, P; Furnari, M; Gemignani, L; Giannini, EG; Moscatelli, A; Savarino, E; Savarino, V; Zentilin, P, 2012) |
| "Among irritable bowel syndrome (IBS) patients, breath methane producers overwhelmingly have constipation predominance (C-IBS)." | 7.78 | Methanobrevibacter smithii is the predominant methanogen in patients with constipation-predominant IBS and methane on breath. ( Chang, C; Deepinder, F; Gunsalus, R; Hwang, L; Kim, G; Morales, W; Pimentel, M; Weitsman, S, 2012) |
| "Methane-producing IBS patients have a unique cluster of symptoms related to constipation." | 7.77 | Factor analysis demonstrates a symptom cluster related to methane and non-methane production in irritable bowel syndrome. ( Low, K; Makhani, M; Mirocha, J; Pimentel, M; Yang, J, 2011) |
| " Among these findings, methane production is more commonly associated with constipation-predominant symptoms." | 7.76 | Evaluating breath methane as a diagnostic test for constipation-predominant IBS. ( Hwang, L; Khoshini, R; Low, K; Makhani, M; Melmed, G; Pimentel, M; Pokkunuri, V; Sahakian, A, 2010) |
| "The presence of breath methane in children with chronic constipation may suggest the possibility of prolonged colonic transit time." | 7.73 | Breath methane associated with slow colonic transit time in children with chronic constipation. ( de Morais, MB; Fagundes-Neto, U; Lederman, HM; Soares, AC, 2005) |
| "4% and specificity of 100% for diagnosing IMO on the glucose and lactulose breath tests and was associated with constipation (5." | 5.51 | A Single Fasting Exhaled Methane Level Correlates With Fecal Methanogen Load, Clinical Symptoms and Accurately Detects Intestinal Methanogen Overgrowth. ( Chang, C; Hosseini, A; Kowalewski, E; Leite, G; Mathur, R; Morales, W; Pimentel, M; Rao, S; Rashid, M; Rezaie, A; Sanchez, M; Takakura, W; Torosyan, J; Villanueva-Millan, MJ; Wang, J, 2022) |
| "Constipation is a common symptom affecting up to 30% of the Western population and is strongly associated with the presence of intestinal methanogens, which may directly inhibit motor activity." | 5.46 | Effect of Lactobacillus reuteri (DSM 17938) on methane production in patients affected by functional constipation: a retrospective study. ( Franceschi, F; Gasbarrini, A; Gnarra, M; Migneco, A; Ojetti, V; Petruzziello, C, 2017) |
| "Methane production was associated with the composition of the fecal microbiota, but not with constipation or colonic transit." | 5.43 | Relationship Between Microbiota of the Colonic Mucosa vs Feces and Symptoms, Colonic Transit, and Methane Production in Female Patients With Chronic Constipation. ( Bharucha, AE; Chen, J; Chen, X; Chia, N; Gaskins, HR; O'Connor, HM; Parthasarathy, G; Wolf, PG, 2016) |
| "Methane production has been associated with chronic constipation (CC) and with changes in gut motility." | 5.42 | Breath methane in functional constipation: response to treatment with Ispaghula husk. ( Abad, A; Andreu, V; Barenys, M; García Bayo, I; García, M; Martos, L; Perelló, A; Vega, AB, 2015) |
| "Methane excretion was present in 26 of 40 (65%) encopretic patients versus 6 of 40 (15%) control patients (P less than 0." | 5.28 | Breath methane production in children with constipation and encopresis. ( Casteel, HB; Fiedorek, SC; Pumphrey, CL, 1990) |
| "Bristol stool form, frequency, colon transit time (CTT), and breath methane were evaluated in 23 patients with CC (10 patients with constipation-predominant irritable bowel syndrome [IBS-C], 13 functional constipation, Rome III) and m-ethane production compared with 68 non-constipating IBS." | 5.27 | A randomized double-blind placebo-controlled trial showing rifaximin to improve constipation by reducing methane production and accelerating colon transit: A pilot study. ( Ghoshal, UC; Misra, A; Srivastava, D, 2018) |
| " Methane production is associated with constipation and its severity in constipation-predominant IBS (C-IBS)." | 5.19 | Antibiotic treatment of constipation-predominant irritable bowel syndrome. ( Amichai, M; Chang, C; Chua, KS; DiBaise, J; Mirocha, J; Pimentel, M; Rao, S, 2014) |
| "Adjuvant 5-fluorouracil chemotherapy reduces recurrences in colorectal cancer, but causes severe gastrointestinal toxicity, partly related to disturbed intestinal microbiota." | 5.17 | Colonic methane production modifies gastrointestinal toxicity associated with adjuvant 5-fluorouracil chemotherapy for colorectal cancer. ( Blom, M; Holma, R; Korpela, R; Osterlund, P; Poussa, T; Rautio, M; Sairanen, U; Saxelin, M, 2013) |
| "Recent work has demonstrated that among irritable bowel syndrome (IBS) subjects, methane on lactulose breath test (LBT) is nearly universally associated with constipation predominance." | 5.12 | The degree of breath methane production in IBS correlates with the severity of constipation. ( Chatterjee, S; Kong, Y; Low, K; Park, S; Pimentel, M, 2007) |
| " This subanalysis was done on the constipation-predominant IBS subgroup of patients (C-IBS) to test the ability of neomycin to improve constipation and its correlation with the elimination of methane on breath test." | 5.12 | Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: subanalysis of a double-blind randomized controlled study. ( Chatterjee, S; Chow, EJ; Kong, Y; Park, S; Pimentel, M, 2006) |
| "A growing body of literature suggests an association between methane and constipation." | 4.87 | Methane on breath testing is associated with constipation: a systematic review and meta-analysis. ( Basseri, RJ; Chang, C; Chong, K; Kunkel, D; Makhani, MD; Pimentel, M, 2011) |
| " A total of 231 patients with clinical hypothyroidism during the second trimester of pregnancy and 210 normal pregnant women were enrolled in the lactulose methane-hydrogen breath test." | 4.12 | Efficacy evaluation of probiotics combined with prebiotics in patients with clinical hypothyroidism complicated with small intestinal bacterial overgrowth during the second trimester of pregnancy. ( Ban, Y; Cai, Y; Hao, Y; Li, J; Ouyang, Q; Sun, Z; Wang, M; Wang, W; Wu, B; Xu, Y; Zhang, M, 2022) |
| "Consecutive Asian adults with Rome III diagnosed common FGIDs (functional dyspepsia/FD, IBS and functional constipation/FC) and non-FGID controls were subjected to glucose breath testing, with hydrogen (H2) and methane (CH4) levels determined." | 4.12 | Small Intestinal Bacterial Overgrowth In Various Functional Gastrointestinal Disorders: A Case-Control Study. ( Beh, KH; Chong, SCS; Chuah, KH; Lee, YY; Lim, SZ; Mahadeva, S; Tan, PO; Thalha, AM; Wong, MS; Zulkifli, KK, 2022) |
| "We found that constipation and bloating severity did not correlate with methane levels on GBT." | 3.96 | Breath Methane Does Not Correlate With Constipation Severity or Bloating in Patients With Constipation. ( Ballou, S; Duehren, S; Iturrino, J; Katon, J; Lembo, A; Nee, J; Patel, R; Rangan, V; Singh, P, 2020) |
| "Rectocele with constipation might be related to methane (CH4) producing intestinal bacteria." | 3.88 | The association between a positive lactulose methane breath test and rectocele in constipated patients. ( Chung, WC; Kim, DB; Kim, YJ; Lee, JM; Lee, KM; Paik, CN; Yang, JM, 2018) |
| "There is growing evidence that methane production, predominantly by Methanobrevibacter smithii, in the intestines is a cause of constipation, pain, and bloating in irritable bowel syndrome with constipation (IBS-C)." | 3.88 | Development of a Modified-Release Formulation of Lovastatin Targeted to Intestinal Methanogens Implicated in Irritable Bowel Syndrome With Constipation. ( Bristol, A; Chadwick, A; Coughlin, O; Hubert, S; Kokai-Kun, J; Wacher, V, 2018) |
| "Differences in the gut microbiota and breath methane production have been observed in chronic constipation, but the relationship between colonic microbiota, transit, and breath tests remains unclear." | 3.85 | Assessing the colonic microbiome, hydrogenogenic and hydrogenotrophic genes, transit and breath methane in constipation. ( Bharucha, AE; Chen, J; Chia, N; Gaskins, HR; O'Connor, HM; Parthasarathy, G; Wolf, PG, 2017) |
| "Lactulose breath test graphs of 561 patients of all irritable bowel syndrome subtypes were grouped into categories based on their hydrogen + methane levels with respect to time." | 3.83 | Predicting a Response to Antibiotics in Patients with the Irritable Bowel Syndrome. ( Adler, M; Dhingra, S; Guttermuth, C; Kasir, R; Lee, A; Zakko, P; Zakko, S, 2016) |
| "Methane (CH4)-producing intestinal bacteria might be related to constipation." | 3.79 | Breath methane positivity is more common and higher in patients with objectively proven delayed transit constipation. ( Choi, MG; Chung, WC; Lee, KM; Paik, CN; Yang, JM, 2013) |
| "Methane excretion is clearly associated with alterations in intestinal motility, particularly favouring those with constipation." | 3.78 | Reassessment of the role of methane production between irritable bowel syndrome and functional constipation. ( Bruzzone, L; Dulbecco, P; Furnari, M; Gemignani, L; Giannini, EG; Moscatelli, A; Savarino, E; Savarino, V; Zentilin, P, 2012) |
| "Among irritable bowel syndrome (IBS) patients, breath methane producers overwhelmingly have constipation predominance (C-IBS)." | 3.78 | Methanobrevibacter smithii is the predominant methanogen in patients with constipation-predominant IBS and methane on breath. ( Chang, C; Deepinder, F; Gunsalus, R; Hwang, L; Kim, G; Morales, W; Pimentel, M; Weitsman, S, 2012) |
| "Methane-producing IBS patients have a unique cluster of symptoms related to constipation." | 3.77 | Factor analysis demonstrates a symptom cluster related to methane and non-methane production in irritable bowel syndrome. ( Low, K; Makhani, M; Mirocha, J; Pimentel, M; Yang, J, 2011) |
| " Among these findings, methane production is more commonly associated with constipation-predominant symptoms." | 3.76 | Evaluating breath methane as a diagnostic test for constipation-predominant IBS. ( Hwang, L; Khoshini, R; Low, K; Makhani, M; Melmed, G; Pimentel, M; Pokkunuri, V; Sahakian, A, 2010) |
| "The presence of breath methane in children with chronic constipation may suggest the possibility of prolonged colonic transit time." | 3.73 | Breath methane associated with slow colonic transit time in children with chronic constipation. ( de Morais, MB; Fagundes-Neto, U; Lederman, HM; Soares, AC, 2005) |
| " Since there are two gases (hydrogen and methane) measured on lactulose breath testing, we evaluated whether the different gas patterns on lactulose breath testing coincide with diarrhea and constipation symptoms in IBS and IBD." | 3.72 | Methane production during lactulose breath test is associated with gastrointestinal disease presentation. ( Chow, EJ; Hasan, A; Kong, Y; Mayer, AG; Park, S; Pimentel, M, 2003) |
| "We have previously shown that methane on lactulose breath test (LBT) is highly associated with constipation in IBS and that methane gas itself slows small bowel transit in dogs." | 3.72 | IBS subjects with methane on lactulose breath test have lower postprandial serotonin levels than subjects with hydrogen. ( Kong, Y; Park, S; Pimentel, M, 2004) |
| "Constipation is very pervasive all over the world." | 2.82 | Gut microbiota: a new avenue to reveal pathological mechanisms of constipation. ( Duan, J; Jiang, S; Li, W; Qian, D; Wang, Y; Yang, L; Zhang, Y, 2022) |
| "Constipation is a common symptom affecting up to 30% of the Western population and is strongly associated with the presence of intestinal methanogens, which may directly inhibit motor activity." | 1.46 | Effect of Lactobacillus reuteri (DSM 17938) on methane production in patients affected by functional constipation: a retrospective study. ( Franceschi, F; Gasbarrini, A; Gnarra, M; Migneco, A; Ojetti, V; Petruzziello, C, 2017) |
| "Methane production was associated with the composition of the fecal microbiota, but not with constipation or colonic transit." | 1.43 | Relationship Between Microbiota of the Colonic Mucosa vs Feces and Symptoms, Colonic Transit, and Methane Production in Female Patients With Chronic Constipation. ( Bharucha, AE; Chen, J; Chen, X; Chia, N; Gaskins, HR; O'Connor, HM; Parthasarathy, G; Wolf, PG, 2016) |
| "Methane production has been associated with chronic constipation (CC) and with changes in gut motility." | 1.42 | Breath methane in functional constipation: response to treatment with Ispaghula husk. ( Abad, A; Andreu, V; Barenys, M; García Bayo, I; García, M; Martos, L; Perelló, A; Vega, AB, 2015) |
| "Methane excretion was present in 26 of 40 (65%) encopretic patients versus 6 of 40 (15%) control patients (P less than 0." | 1.28 | Breath methane production in children with constipation and encopresis. ( Casteel, HB; Fiedorek, SC; Pumphrey, CL, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (7.50) | 18.7374 |
| 1990's | 1 (2.50) | 18.2507 |
| 2000's | 5 (12.50) | 29.6817 |
| 2010's | 26 (65.00) | 24.3611 |
| 2020's | 5 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Takakura, W | 1 |
| Pimentel, M | 11 |
| Rao, S | 2 |
| Villanueva-Millan, MJ | 1 |
| Chang, C | 4 |
| Morales, W | 2 |
| Sanchez, M | 1 |
| Torosyan, J | 1 |
| Rashid, M | 1 |
| Hosseini, A | 1 |
| Wang, J | 1 |
| Leite, G | 1 |
| Kowalewski, E | 1 |
| Mathur, R | 1 |
| Rezaie, A | 1 |
| Yang, L | 1 |
| Wang, Y | 1 |
| Zhang, Y | 1 |
| Li, W | 1 |
| Jiang, S | 1 |
| Qian, D | 1 |
| Duan, J | 1 |
| Hao, Y | 1 |
| Xu, Y | 1 |
| Ban, Y | 1 |
| Li, J | 1 |
| Wu, B | 1 |
| Ouyang, Q | 1 |
| Sun, Z | 1 |
| Zhang, M | 1 |
| Cai, Y | 1 |
| Wang, M | 1 |
| Wang, W | 1 |
| Chuah, KH | 1 |
| Wong, MS | 1 |
| Tan, PO | 1 |
| Lim, SZ | 1 |
| Beh, KH | 1 |
| Chong, SCS | 1 |
| Zulkifli, KK | 1 |
| Thalha, AM | 1 |
| Mahadeva, S | 1 |
| Lee, YY | 1 |
| Ojetti, V | 2 |
| Petruzziello, C | 1 |
| Migneco, A | 1 |
| Gnarra, M | 1 |
| Gasbarrini, A | 2 |
| Franceschi, F | 1 |
| Hubert, S | 1 |
| Chadwick, A | 1 |
| Wacher, V | 2 |
| Coughlin, O | 1 |
| Kokai-Kun, J | 1 |
| Bristol, A | 1 |
| Pennisi, E | 1 |
| Lee, JM | 1 |
| Paik, CN | 2 |
| Kim, YJ | 1 |
| Kim, DB | 1 |
| Chung, WC | 2 |
| Lee, KM | 2 |
| Yang, JM | 2 |
| Shah, A | 1 |
| Morrison, M | 1 |
| Holtmann, G | 1 |
| Ghoshal, UC | 2 |
| Srivastava, D | 2 |
| Misra, A | 1 |
| Singh, P | 1 |
| Duehren, S | 1 |
| Katon, J | 1 |
| Rangan, V | 1 |
| Ballou, S | 1 |
| Patel, R | 1 |
| Iturrino, J | 1 |
| Lembo, A | 1 |
| Nee, J | 1 |
| Bruno, G | 1 |
| Paolucci, V | 1 |
| Triarico, S | 1 |
| D'aversa, F | 1 |
| Ausili, E | 1 |
| Rendeli, C | 1 |
| Chua, KS | 1 |
| Mirocha, J | 2 |
| DiBaise, J | 1 |
| Amichai, M | 1 |
| Vega, AB | 1 |
| Perelló, A | 1 |
| Martos, L | 1 |
| García Bayo, I | 1 |
| García, M | 1 |
| Andreu, V | 1 |
| Abad, A | 1 |
| Barenys, M | 1 |
| Kasir, R | 1 |
| Zakko, S | 1 |
| Zakko, P | 1 |
| Adler, M | 1 |
| Lee, A | 1 |
| Dhingra, S | 1 |
| Guttermuth, C | 1 |
| Parthasarathy, G | 2 |
| Chen, J | 2 |
| Chen, X | 1 |
| Chia, N | 2 |
| O'Connor, HM | 2 |
| Wolf, PG | 2 |
| Gaskins, HR | 2 |
| Bharucha, AE | 2 |
| Gottlieb, K | 1 |
| Sliman, J | 1 |
| Quigley, EM | 1 |
| Spiller, RC | 1 |
| Yazici, C | 1 |
| Arslan, DC | 1 |
| Abraham, R | 1 |
| Cushing, K | 1 |
| Keshavarzian, A | 1 |
| Mutlu, EA | 1 |
| Ghoshal, U | 1 |
| Shukla, R | 1 |
| Hwang, L | 2 |
| Low, K | 3 |
| Khoshini, R | 1 |
| Melmed, G | 1 |
| Sahakian, A | 1 |
| Makhani, M | 2 |
| Pokkunuri, V | 1 |
| Attaluri, A | 1 |
| Jackson, M | 1 |
| Valestin, J | 1 |
| Rao, SS | 1 |
| Yang, J | 1 |
| Di Stefano, M | 1 |
| Corazza, GR | 1 |
| Kunkel, D | 1 |
| Basseri, RJ | 1 |
| Makhani, MD | 1 |
| Chong, K | 1 |
| de Morais, MB | 2 |
| Soares, AC | 2 |
| Tahan, S | 1 |
| Kim, G | 1 |
| Deepinder, F | 1 |
| Weitsman, S | 1 |
| Gunsalus, R | 1 |
| Furnari, M | 1 |
| Savarino, E | 1 |
| Bruzzone, L | 1 |
| Moscatelli, A | 1 |
| Gemignani, L | 1 |
| Giannini, EG | 1 |
| Zentilin, P | 1 |
| Dulbecco, P | 1 |
| Savarino, V | 1 |
| Holma, R | 1 |
| Korpela, R | 1 |
| Sairanen, U | 1 |
| Blom, M | 1 |
| Rautio, M | 1 |
| Poussa, T | 1 |
| Saxelin, M | 1 |
| Osterlund, P | 1 |
| Choi, MG | 1 |
| Mayer, AG | 1 |
| Park, S | 4 |
| Chow, EJ | 2 |
| Hasan, A | 1 |
| Kong, Y | 4 |
| BRASSINNE, A | 1 |
| TRINDADE, MD | 1 |
| Lederman, HM | 1 |
| Fagundes-Neto, U | 1 |
| Chatterjee, S | 2 |
| Fiedorek, SC | 1 |
| Pumphrey, CL | 1 |
| Casteel, HB | 1 |
| Jurgeit, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of the Efficacy and Safety of Single, Daily Oral Doses of SYN-010 Compared to Placebo in Adult Patients With Irritable Bowel Syndrome With Constipation (EASE-DO)[NCT03763175] | Phase 2 | 59 participants (Actual) | Interventional | 2018-12-24 | Terminated (stopped due to Interim Futility Analysis) | ||
| A Randomized Open Label Trial Evaluating the Efficacy of AEMCOLO (Rifamycin SV MMX) in the Treatment of Small Intestinal Bacterial Overgrowth (SIBO)[NCT04501380] | Phase 2 | 30 participants (Anticipated) | Interventional | 2020-06-30 | Enrolling by invitation | ||
| A Randomized Controlled Trial of the Safety and Efficacy of Fecal Microbiota Transplantation in a Population With Bipolar Disorder[NCT03279224] | Phase 2/Phase 3 | 35 participants (Actual) | Interventional | 2018-01-01 | Active, not recruiting | ||
| Efficacy of the Supplementation With a Symbiotic, a Prebiotic and a Probiotic to Produce a Beneficial Effect on the Intestinal Microbiota and on the Characteristics of Feces in Children With Cerebral Palsy (CP) and Chronic Constipation[NCT03117322] | Phase 4 | 40 participants (Actual) | Interventional | 2017-06-05 | Completed | ||
| Evaluation of the Efficacy and Safety of Rifaximin in Combination With N-acetylcysteine (NAC) in Adult Patients With Irritable Bowel Syndrome With Diarrhea[NCT04557215] | Phase 1/Phase 2 | 45 participants (Actual) | Interventional | 2020-11-13 | Completed | ||
| Effects of Rifaximin on Visceral Hypersensitivity in Irritable Bowel Syndrome[NCT03462966] | Phase 2 | 4 participants (Actual) | Interventional | 2018-07-01 | Terminated (stopped due to recruitment challenges) | ||
| Double-blind, Placebo Controlled Trial Comparing Neomycin to Rifaximin Plus Neomycin in the Treatment of Methane Positive Subjects With Constipation-predominant Irritable Bowel Syndrome[NCT00945334] | 37 participants (Actual) | Interventional | 2009-08-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in exhaled methane level as a potential predictor of constipation improvement will be evaluated by comparing single-point breath tests pre- and post-treatment. (NCT03763175)
Timeframe: After completing course of SYN-010
| Intervention | particles per million (Mean) |
|---|---|
| SYN-010 21 mg | -22.623 |
| SYN-010 42 mg | -4.785 |
| Placebo | -10.081 |
Subjects will record their daily bowel movements throughout the duration of the study. Change in weekly average number of CSBMs will be evaluated by comparing reported values pre- and post-treatment. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010
| Intervention | Weekly average CSBMs (Least Squares Mean) |
|---|---|
| SYN-010 21 mg | 1.53 |
| SYN-010 42 mg | 0.32 |
| Placebo | 0.51 |
Change in exhaled methane level as a potential predictor of constipation improvement will be evaluated by comparing lactulose breath tests pre- and post-treatment. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010
| Intervention | particles per million * min (Mean) |
|---|---|
| SYN-010 21 mg | -18.678 |
| SYN-010 42 mg | -20.137 |
| Placebo | -39.199 |
An overall abdominal pain intensity responder is defined as a patient with a weekly abdominal pain intensity response in at least 50% of the weeks of treatment (6 of 12 weeks). A weekly response abdominal pain intensity response is defined as a decrease in the patient's weekly average score for worst abdominal pain in the past 24 hours of at least 30% compared to baseline, with stool frequency unchanged or improved compared with baseline. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010
| Intervention | Participants (Count of Participants) |
|---|---|
| SYN-010 21 mg | 4 |
| SYN-010 42 mg | 4 |
| Placebo | 7 |
An overall bloating responder is defined as a patient with a weekly bloating response in at least 50% of the weeks of treatment (6 of 12 weeks). A weekly bloating response is defined as a weekly average bloating score of at least 30% improvement compared to baseline, with stool frequency unchanged or improved compared with baseline. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010
| Intervention | Participants (Count of Participants) |
|---|---|
| SYN-010 21 mg | 3 |
| SYN-010 42 mg | 3 |
| Placebo | 1 |
An overall 12-week responder is defined as a patient with a weekly response in at least 50% of the weeks of treatment (6 of 12 weeks). A weekly response is defined as a decrease in the patient's weekly average score for worst abdominal pain in the past 24 hours of at least 30% compared to baseline and a stool frequency increase of 1 or more CSBMs per week compared with baseline. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010
| Intervention | Participants (Count of Participants) |
|---|---|
| SYN-010 21 mg | 1 |
| SYN-010 42 mg | 2 |
| Placebo | 6 |
An overall stool frequency responder is defined as a patient with a weekly stool frequency response in at least 50% of the weeks of treatment (6 of 12 weeks). A weekly stool frequency response is defined as a stool frequency increase of 1 or more CSBMs per week compared with baseline, with abdominal pain unchanged or improved compared with baseline. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010
| Intervention | Participants (Count of Participants) |
|---|---|
| SYN-010 21 mg | 4 |
| SYN-010 42 mg | 6 |
| Placebo | 9 |
Subjects will record their use of rescue medication throughout the study period. Proportion of patients using rescue medication after completing the 12-week course of treatment will be compared to those reporting usage at baseline screening period. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010
| Intervention | Participants (Count of Participants) |
|---|---|
| SYN-010 21 mg | 9 |
| SYN-010 42 mg | 11 |
| Placebo | 8 |
Outcome will be assessed by evaluating proportion of patients reporting adequate relief pre- and post-treatment on validated questionnaire. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010
| Intervention | Participants (Count of Participants) |
|---|---|
| SYN-010 21 mg | 1 |
| SYN-010 42 mg | 2 |
| Placebo | 6 |
"Change in severity of abdominal pain from baseline, as determined from weekly average visual analog scale (VAS) scores, relative to Rifaximin alone. VAS scores allows subject to choose 0 for no pain to 100 pain as bad as it could possibly be.~The Visual Analogue Scale (VAS) measures pain intensity. The VAS consists of a 10cm line, with two end points representing 0 no pain and 100 pain as bad as it could possibly be~The change between two time points is reported baseline and 4 weeks after cessation of treatment (at 6 weeks)" (NCT04557215)
Timeframe: value at 6 weeks minus value at baseline
| Intervention | units on a scale (Mean) |
|---|---|
| Rifaximin 550 mg | -5.43 |
| Rifaximin 200 mg + Placebo | -8.90 |
| Rifaximin 200 mg Plus N-acetylcysteine (NAC) 600 mg Days | -5.59 |
"Change in stool form from baseline, as determined from stool diary data comparing Rifaximin alone vs rifaximin and NAC~The Bristol Stool Chart, the minimum value is 1 (means constipation) and maximum value is 7 (means diarrhea).~The change between two time points is reported baseline and 4 weeks after cessation of treatment (at 6 weeks)" (NCT04557215)
Timeframe: value at 6 weeks minus value at baseline
| Intervention | score on a scale (Mean) |
|---|---|
| Rifaximin 550 mg | -0.26 |
| Rifaximin 200 mg + Placebo | -0.45 |
| Rifaximin 200 mg Plus N-acetylcysteine (NAC) 600 mg Days | -0.49 |
"Change in stool frequency from baseline, as determined from diary data comparing Rifaximin alone vs Rifaximin and NAC~determined from daily stool diary data~The change in bowel movements/day between two time points is reported baseline and 4 weeks after cessation of treatment (at 6 weeks)" (NCT04557215)
Timeframe: value at 6 weeks minus value at baseline
| Intervention | number of bowel movements (Mean) |
|---|---|
| Rifaximin 550 mg | -0.04 |
| Rifaximin 200 mg + Placebo | -0.50 |
| Rifaximin 200 mg Plus N-acetylcysteine (NAC) 600 mg Days | -0.24 |
Association of urgency symptom and rectal sensitivity will be evaluated by the mean change in the balloon pressure (measured in mmHg) that leads to first urge sensation to defecate, evaluated based on the visual analogue scale defined in the primary outcome measure. (NCT03462966)
Timeframe: After completing 14-day course of rifaximin.
| Intervention | Millimetre of mercury (Mean) |
|---|---|
| Therapeutic | 106 |
A 100-cubic centimeter visual analogue scale with verbal descriptors (0=no sensation, 20=first sensation, 40=first sense of urge, 60=normal urge to defecate, 80=severe urge to defecate, and 100=discomfort/pain) will be used to score evoked sensations. (NCT03462966)
Timeframe: After completing 14-day course of rifaximin.
| Intervention | volume cubic centimeter (Mean) |
|---|---|
| Therapeutic | 37.5 |
"Normalization of lactulose breath test as a potential predictor of improvement of rectal hypersensitivity will be evaluated by comparing lactulose breath test results pre- and post-treatment.~Normalization of lactulose breath test defined as rise of hydrogen <20 Parts per million within 90 minutes of lactulose ingestion.~patients with positive" (NCT03462966)
Timeframe: After completing 14-day course of rifaximin
| Intervention | Participants (Count of Participants) |
|---|---|
| Therapeutic | 2 |
"Methane output was reported as methane in parts per million (ppm) on breath test:~Subjects fast for 12 h prior to a breath sample. Breath samples were collected via a Quintron dual bag collecting system and analyzed using a BreathTracker SC. Output was reported as methane in parts per million (ppm) after correction for alveolar sample quality using breath CO2 concentration." (NCT00945334)
Timeframe: Baseline (Day 0) and Final Visit (Day 44)
| Intervention | parts per million (Median) |
|---|---|
| Group 1 | 7.5 |
| Group 2 | 15 |
"Visual analog scale (VAS) score for constipation:~Severity was rated using a VAS from 0 to 100 units (with 0 = no symptom and 100 = severe symptoms)." (NCT00945334)
Timeframe: 1 year
| Intervention | units on a scale (Mean) |
|---|---|
| Group 1 | 61.2 |
| Group 2 | 28.6 |
3 reviews available for methane and Constipation
| Article | Year |
|---|---|
Gut microbiota: a new avenue to reveal pathological mechanisms of constipation.
Topics: Bile Acids and Salts; Constipation; Fatty Acids, Volatile; Gastrointestinal Microbiome; Humans; Meth | 2022 |
Review article: inhibition of methanogenic archaea by statins as a targeted management strategy for constipation and related disorders.
Topics: Archaea; Constipation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Irritable Bowel Syndr | 2016 |
Methane on breath testing is associated with constipation: a systematic review and meta-analysis.
Topics: Breath Tests; Constipation; Humans; Methane | 2011 |
7 trials available for methane and Constipation
| Article | Year |
|---|---|
A Single Fasting Exhaled Methane Level Correlates With Fecal Methanogen Load, Clinical Symptoms and Accurately Detects Intestinal Methanogen Overgrowth.
Topics: Anti-Bacterial Agents; Breath Tests; Constipation; Fasting; Glucose; Humans; Irritable Bowel Syndrom | 2022 |
A randomized double-blind placebo-controlled trial showing rifaximin to improve constipation by reducing methane production and accelerating colon transit: A pilot study.
Topics: Adolescent; Adult; Aged; Breath Tests; Colon; Constipation; Double-Blind Method; Feces; Female; Gast | 2018 |
Antibiotic treatment of constipation-predominant irritable bowel syndrome.
Topics: Adult; Anti-Infective Agents; Breath Tests; Constipation; Female; Gastrointestinal Agents; Humans; I | 2014 |
Colonic methane production modifies gastrointestinal toxicity associated with adjuvant 5-fluorouracil chemotherapy for colorectal cancer.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Breath Tests; Carcinoma; Chemotherapy, Adj | 2013 |
Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: subanalysis of a double-blind randomized controlled study.
Topics: Adult; Anti-Bacterial Agents; Breath Tests; Constipation; Double-Blind Method; Female; Follow-Up Stu | 2006 |
Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: subanalysis of a double-blind randomized controlled study.
Topics: Adult; Anti-Bacterial Agents; Breath Tests; Constipation; Double-Blind Method; Female; Follow-Up Stu | 2006 |
Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: subanalysis of a double-blind randomized controlled study.
Topics: Adult; Anti-Bacterial Agents; Breath Tests; Constipation; Double-Blind Method; Female; Follow-Up Stu | 2006 |
Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: subanalysis of a double-blind randomized controlled study.
Topics: Adult; Anti-Bacterial Agents; Breath Tests; Constipation; Double-Blind Method; Female; Follow-Up Stu | 2006 |
Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: subanalysis of a double-blind randomized controlled study.
Topics: Adult; Anti-Bacterial Agents; Breath Tests; Constipation; Double-Blind Method; Female; Follow-Up Stu | 2006 |
Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: subanalysis of a double-blind randomized controlled study.
Topics: Adult; Anti-Bacterial Agents; Breath Tests; Constipation; Double-Blind Method; Female; Follow-Up Stu | 2006 |
Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: subanalysis of a double-blind randomized controlled study.
Topics: Adult; Anti-Bacterial Agents; Breath Tests; Constipation; Double-Blind Method; Female; Follow-Up Stu | 2006 |
Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: subanalysis of a double-blind randomized controlled study.
Topics: Adult; Anti-Bacterial Agents; Breath Tests; Constipation; Double-Blind Method; Female; Follow-Up Stu | 2006 |
Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: subanalysis of a double-blind randomized controlled study.
Topics: Adult; Anti-Bacterial Agents; Breath Tests; Constipation; Double-Blind Method; Female; Follow-Up Stu | 2006 |
The degree of breath methane production in IBS correlates with the severity of constipation.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Breath Tests; Case-Control Studies; Constipation; Dou | 2007 |
[Trial of a rapid-acting laxative (Laxagetten--suppositories)].
Topics: Acetates; Cathartics; Clinical Trials as Topic; Constipation; Cresols; Defecation; Humans; Indoles; | 1971 |
30 other studies available for methane and Constipation
| Article | Year |
|---|---|
Efficacy evaluation of probiotics combined with prebiotics in patients with clinical hypothyroidism complicated with small intestinal bacterial overgrowth during the second trimester of pregnancy.
Topics: Apolipoproteins; Apolipoproteins B; C-Reactive Protein; Cholesterol; Constipation; Fatty Acids, None | 2022 |
Small Intestinal Bacterial Overgrowth In Various Functional Gastrointestinal Disorders: A Case-Control Study.
Topics: Adult; Breath Tests; Case-Control Studies; Constipation; Humans; Intestine, Small; Irritable Bowel S | 2022 |
Effect of Lactobacillus reuteri (DSM 17938) on methane production in patients affected by functional constipation: a retrospective study.
Topics: Adult; Constipation; Female; Humans; Lactulose; Limosilactobacillus reuteri; Methane; Probiotics; Re | 2017 |
Development of a Modified-Release Formulation of Lovastatin Targeted to Intestinal Methanogens Implicated in Irritable Bowel Syndrome With Constipation.
Topics: Animals; Anticholesteremic Agents; Chemistry, Pharmaceutical; Constipation; Dogs; Drug Delivery Syst | 2018 |
Survey of archaea in the body reveals other microbial guests.
Topics: Constipation; Digestion; Gastrointestinal Microbiome; Gastrointestinal Tract; Humans; Lung; Methane; | 2017 |
The association between a positive lactulose methane breath test and rectocele in constipated patients.
Topics: Adult; Aged; Breath Tests; Colon; Constipation; Female; Humans; Lactulose; Male; Methane; Middle Age | 2018 |
A novel treatment for patients with constipation: Dawn of a new age for translational microbiome research?
Topics: Colon; Constipation; Double-Blind Method; Humans; Methane; Microbiota; Pilot Projects; Rifaximin | 2018 |
Breath Methane Does Not Correlate With Constipation Severity or Bloating in Patients With Constipation.
Topics: Breath Tests; Constipation; Diarrhea; Humans; Irritable Bowel Syndrome; Methane | 2020 |
The prevalence of small intestinal bacterial overgrowth and methane production in patients with myelomeningocele and constipation.
Topics: Adolescent; Breath Tests; Constipation; Female; Flatulence; Gastrointestinal Transit; Humans; Intest | 2014 |
Breath methane in functional constipation: response to treatment with Ispaghula husk.
Topics: Adult; Breath Tests; Cathartics; Colon; Constipation; Female; Gastrointestinal Transit; Humans; Male | 2015 |
Predicting a Response to Antibiotics in Patients with the Irritable Bowel Syndrome.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Breath Tests; Constipation; Diarrhea; Fema | 2016 |
Relationship Between Microbiota of the Colonic Mucosa vs Feces and Symptoms, Colonic Transit, and Methane Production in Female Patients With Chronic Constipation.
Topics: Adult; Algorithms; Bacteria; Breath Tests; Case-Control Studies; Chronic Disease; Colon; Constipatio | 2016 |
Constipation and the Microbiome: Lumen Versus Mucosa!
Topics: Bacteria; Colon; Constipation; Feces; Female; Gastrointestinal Microbiome; Gastrointestinal Transit; | 2016 |
Breath Methane Levels Are Increased Among Patients with Diverticulosis.
Topics: Age Factors; Antihypertensive Agents; Breath Tests; Case-Control Studies; Celiac Disease; Colonoscop | 2016 |
Irritable Bowel Syndrome, Particularly the Constipation-Predominant Form, Involves an Increase in
Topics: Adult; Aged; Area Under Curve; Breath Tests; Case-Control Studies; Constipation; Diarrhea; Feces; Fe | 2016 |
Assessing the colonic microbiome, hydrogenogenic and hydrogenotrophic genes, transit and breath methane in constipation.
Topics: Adult; Breath Tests; Constipation; DNA, Bacterial; Female; Gastrointestinal Microbiome; Gastrointest | 2017 |
Evaluating breath methane as a diagnostic test for constipation-predominant IBS.
Topics: Adult; Breath Tests; Constipation; Diagnosis, Differential; Female; Follow-Up Studies; Humans; Irrit | 2010 |
Methanogenic flora is associated with altered colonic transit but not stool characteristics in constipation without IBS.
Topics: Adult; Aged; Colon; Constipation; Feces; Gastrointestinal Transit; Humans; Irritable Bowel Syndrome; | 2010 |
Factor analysis demonstrates a symptom cluster related to methane and non-methane production in irritable bowel syndrome.
Topics: Breath Tests; Constipation; Diarrhea; Factor Analysis, Statistical; Humans; Irritable Bowel Syndrome | 2011 |
Methanogenic flora and constipation: many doubts for a pathogenetic link.
Topics: Colon; Constipation; Gastrointestinal Transit; Humans; Methane | 2010 |
Constipation, breath methane, and orocecal transit time for a bean meal test.
Topics: Breath Tests; Child; Constipation; Gastrointestinal Transit; Humans; Intestine, Small; Methane | 2011 |
Methanobrevibacter smithii is the predominant methanogen in patients with constipation-predominant IBS and methane on breath.
Topics: Adult; Breath Tests; Constipation; DNA, Bacterial; Feces; Female; Humans; Hydrogen; Irritable Bowel | 2012 |
Reassessment of the role of methane production between irritable bowel syndrome and functional constipation.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Bacteria; Breath Tests; Constipation; Defec | 2012 |
Breath methane positivity is more common and higher in patients with objectively proven delayed transit constipation.
Topics: Adult; Aged; Aged, 80 and over; Anal Canal; Breath Tests; Constipation; Female; Gastrointestinal Tra | 2013 |
Methane production during lactulose breath test is associated with gastrointestinal disease presentation.
Topics: Breath Tests; Colitis, Ulcerative; Constipation; Crohn Disease; Databases, Factual; Gastrointestinal | 2003 |
[Clinical study of a new laxative: (4-4, diacetoxy-diphenyl)-(pyridyl 2)-methane].
Topics: Biomedical Research; Biphenyl Compounds; Cathartics; Constipation; Humans; Laxatives; Methane | 1958 |
[USE OF A SUPPOSITORY OF 4,4-DIACETOXY-DIPHENYL-PYRIDYL-2-METHANE IN HOSPITAL CLINICAL PRACTICE].
Topics: Biphenyl Compounds; Cathartics; Constipation; Diphenhydramine; Hospitals; Humans; Methane; Supposito | 1964 |
IBS subjects with methane on lactulose breath test have lower postprandial serotonin levels than subjects with hydrogen.
Topics: Adolescent; Adult; Aged; Breath Tests; Chromatography, High Pressure Liquid; Constipation; Diarrhea; | 2004 |
Breath methane associated with slow colonic transit time in children with chronic constipation.
Topics: Adolescent; Breath Tests; Chi-Square Distribution; Child; Child, Preschool; Chronic Disease; Constip | 2005 |
Breath methane production in children with constipation and encopresis.
Topics: Age Factors; Breath Tests; Cathartics; Child; Constipation; Dietary Fiber; Encopresis; Female; Human | 1990 |